On Wednesday, the 6th of January, everyone’s favorite reverse-merger pink sheet Coronacrapper, Cytodyn (CYDY) will be holding the latest in a long series of amusing presentations which we lovingly refer to as “CONference Calls.” This one must be particularly important as the company issued not one, but two press releases about it.
Here is the agenda from the first press release, on the left, and the second, on the right:
Notice the difference? Some important language was added in the second press release. Was it really intended as a reminder to investors or was it a CYA warning to investors?
Lets examine just a few of these agenda items:
There is one particular country that is suspiciously absent from the list in item 1, and by extension item 5, the Philippines. Odd considering how much The NaDDir* and the touts all over the internet have been hyping it. Want to know why an EUA in the Philippines was simply never in the cards for Cytodyn, contrary to all of the misleading hype? Read all about it here.
How about item 3? The potential revenue for Cytodyn from loserlimab, should it ever be approved? Contrary to The NaDDir’s* claims of billions in revenue, the real revenue opportunity for the company is far more modest. Why? Because even loserlimab’s biggest boosters recognize that everything they claim it can do another drug, Selzentry, can already do (and likely do far better for pharmacological reasons). Selzentry is approved and has been on the market for so long there is already a generic version known as maraviroc.
And for all of that supposed CCR5 blocking magic, maraviroc sells a bit over $20mm a quarter in the USA. That’s it. Not 000s of millions, and certainly not billions.
The proper pricing comparison for loserlimab is not remdesivir, but maraviroc, which costs about $1600 per month (300mg pill. 2x a day) without insurance reimbursement.
A shorter course of treatment, say 300mg x2 per day for one or two weeks, for coronavirus, would be about $400-800.
Agenda item 6, is an update on the the “Long Hauler” study. Want an update? Here you go. The study is ALREADY behind schedule. It was supposed to start on December 21, 2020. That date was missed. Now it is scheduled to start on January 21, 2021. It was supposed to be a quick study, lasting only three months, now it is expected to run until late June, a full five months.
For the Cytodummies who don’t believe that, please look it up for yourselves on Clinicaltrials.gov, be sure to click on “History of Changes.”
What about agenda item 8, Breakthrough Therapy Designation for loserlimab? This has already been explored at length in a post the 6th of October. It should set the record straight about Cytodyn’s REAL timeline with regards to applying for Breakthrough Therapy Designation with the FDA. Read it here. Hint: They already have applied, and they have already been rejected.
And then there is agenda item 9, GvHD Trial Status. That trial has been going nowhere fast for five years, and continues to go nowhere. Read all about it here.
Finally, item 11, the much talked about NASDAQ listing. Want to know why a NASDAQ listing is a virtual impossibility, based on currently available audited financials, for Cytodyn? Read all about that here and here.
Tomorrow should certainly be fun.
PS A great read on the Cytodyn CD12 trial is this Twitter thread here.
* Spelled Thusly For A Double Dose of That Sweet Sweet Stock Pimping
more BS from naked sellers strike.
[Can you point out a single factual error? Can you refute anything in the post? Anything at all, Kent? – Editor]
You shorts are getting real desperate lmao. No one believes the garbage you post. This isn’t even news worthy. You’d probably be better at writing fictional children’s books 🤡🤡🤡
[Can you point out a single factual error? Anything, John? – Editor]
Thanks editor. I’m almost out of this stock. Taking a chance to capitalize on the latest pump. It’ll tank on Thursday. At least I’ll be out with most of my capital intact – actually made a little so far. I can’t believe the cult won’t put the blinders down and take an honest and unbiased look at holding Cyto accountable for the misleading, well-spun “activity” this company continually force feeds the sheeple.
I should add that the whole Phillipines dance was an exercise in comical delusion. Oh well….a lot of investors will be in for a shocking lesson.
I dare you to hold a short position right now, dare you too jerkoff, another scumbag who wants to make 600 bucks and doesn’t care that a company wants to save lives. Rot in hell you POS
[Byrd/Jason (same IP address) you sure seem nice – Editor]
LOL maraviroc…good one
There’s literally not a bigger jerkoff out there than you, you use to write hot pieces every couple months and get some damage done a few times but now you write them every other day, you’re scared, you’re showing your cards now by over writing it now, when you call a life saving drug a name you now lose credibility of anybody that you may have been trying to push to sell their shares, nobody takes you seriously anymore not even the weak hands, as you can see last time the panic sell never worked as it bounced back immediately, the longs are so loyal we will never sell shit, this things about to take off and you know it and nadar is gonna bend you all over and be your daddy and you’re gonna be begging for it to stop, once you lose everything and your wife leaves you and your life falls to shit as cytodyn takes billions from gilead, your life will be done. It’s coming, you know it, we all can’t wait to rub it in your face and Adam F as well. It’s gonna be a glorious day and a day that is approaching very fast. Enjoy your last days cause we’re coming for you. Signed F off 💸
[Byrd/Jason (same IP address), can you find a single factual error? – Editor]
Hey Byrd, with facts like that I guess it’s a sure thing eh? Like the CFO selling his shares, like the UK S/C CD12 trial sites, like Nasdaq, like BLA, like Phillipines. Strangely, the FDA doesn’t see Leronlimab “saving lives”, does it? I just don’t want to get suckered into a big dissapointment in Feb. when the warning signs are here all along.
I don’t see a single warning sign that’s bad, I see them filling a full trial up and allowed to fill over that because the data is so amazing and it’s working, I see others being halted and cydy allowed to do what they do and save lives, I see investors all buying up shares in huge numbers and a CD12 the hardest of them all severe trial complete and about to pound shorts so fucking good in a matter of days. All the other countries you speak of are waiting on the data like we all are. Get ready for a rough ride for you shorts